Ulcerative Colitis (UC) is a chronic, or long lasting, disease that causes inflammation—irritation or swelling—and sores called ulcers on the inner lining of the large intestine. It is a chronic inflammatory disease of the gastrointestinal (GI) tract, called inflammatory bowel disease (IBD). It most often begins gradually and can become worse over time. Symptoms can be mild to severe. Most people have periods of remission—times when symptoms disappear—that can last for weeks or years. The goal of care is to keep people in remission long term.
The most common signs and symptoms of UC are diarrhea with blood or pus and abdominal discomfort. Other signs and symptoms include: an urgent need to have a bowel movement; feeling tired; nausea or loss of appetite; weight loss; fever; Anemia. The exact cause of UC is unknown. Researchers believe the following factors may play a role in causing ulcerative colitis: overactive intestinal immune system; genes; environment.
Get FREE sample copy at:
The Ulcerative Colitis market report also covers emerging drugs, current treatment practices, Ulcerative Colitis market share of the individual therapies, current and forecasted Ulcerative Colitis Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Ulcerative Colitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Ulcerative Colitis Market Key Facts
Ulcerative colitis affects males and females in equal numbers. In the United States and Western Europe, the frequency (i.e., prevalence) of the disease is approximately 70 to 150 cases per 100,000 in the general population.
As per the study conducted by Gary R. Lichtenstein et al. (2015), in North America, the incidence of UC is 8 to 20 cases per 100,000 people, and the prevalence is 120 to 250 cases per 100,000 people.
According to the “National Institute of Diabetes and Digestive and Kidney Diseases”, Ulcerative Colitis can occur in people of any age. However, it is more likely to develop in people: between the ages of 15 and 30, older than 60 and who have a family member with IBD.
Key Benefits of Ulcerative Colitis Market Report
Ulcerative Colitis market report provides an in-depth analysis of Ulcerative Colitis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
The Ulcerative Colitis market report will help in developing business strategies by understanding the Ulcerative Colitis Market trends & developments, key players and future market competition that will shape and drive the Ulcerative Colitis market in the upcoming years.
The Ulcerative Colitis market report covers Ulcerative Colitis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
The report provides a detailed assessment of the Ulcerative Colitis market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Ulcerative colitis (UC) is a chronic inflammatory condition associated with rectal bleeding and urgency, tenesmus, and diarrhea. Several medical therapies can be used in the treatment of UC. The primary goals of therapy for patients with UC are to induce remission, maintain remission (ie, minimize risk of relapse), and enhance quality of life.
The treatment needs depends on the severity of the disease and the symptoms. Each person experiences ulcerative colitis differently, so health care providers adjust treatments to improve the person’s symptoms and induce, or bring about, remission.
The Ulcerative Colitis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Ulcerative Colitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Ulcerative Colitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Ulcerative Colitis Epidemiology
The Ulcerative Colitis epidemiology section covers insights about historical and current Ulcerative Colitis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Ulcerative Colitis Drugs Uptake and Key Market Players
The Ulcerative Colitis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ulcerative Colitis market or expected to get launched in the market during the study period. The analysis covers Ulcerative Colitis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Ulcerative Colitis market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period of 2020–2030.
Some of the key companies in the Ulcerative Colitis market includes:
And many others
And many others.
Table of Content
1. Key Insights
2. Executive Summary
3. Ulcerative Colitis Competitive Intelligence Analysis
4. Ulcerative Colitis Market Overview at a Glance
5. Ulcerative Colitis Disease Background and Overview
6. Ulcerative Colitis Patient Journey
7. Ulcerative Colitis Epidemiology and Patient Population
8. Ulcerative Colitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Ulcerative Colitis Unmet Needs
10. Key Endpoints of Ulcerative Colitis Treatment
11. Ulcerative Colitis Marketed Products
12. Ulcerative Colitis Emerging Therapies
13. Ulcerative Colitis Seven Major Market Analysis
14. Attribute Analysis
15. Ulcerative Colitis Market Outlook (7 major markets)
16. Ulcerative Colitis Access and Reimbursement Overview
17. KOL Views on the Ulcerative Colitis Market.
18. Ulcerative Colitis Market Drivers
19. Ulcerative Colitis Market Barriers
21. DelveInsight Capabilities
DelveInsight’s Ulcerative Colitis (UC) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Ulcerative Colitis (UC) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Ulcerative Colitis (UC) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Ulcerative Colitis (UC) market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States